Your browser is no longer supported. Please, upgrade your browser.
OMER Omeros Corporation daily Stock Chart
OMER [NASD]
Omeros Corporation
Index- P/E- EPS (ttm)-2.06 Insider Own0.10% Shs Outstand54.51M Perf Week-6.19%
Market Cap665.88M Forward P/E- EPS next Y-1.80 Insider Trans-7.28% Shs Float48.25M Perf Month9.30%
Income-108.00M PEG- EPS next Q-0.56 Inst Own52.50% Short Float25.62% Perf Quarter-23.37%
Sales100.30M P/S6.64 EPS this Y34.60% Inst Trans0.05% Short Ratio7.72 Perf Half Y-37.06%
Book/sh-2.96 P/B- EPS next Y17.60% ROA-103.60% Target Price- Perf Year-39.01%
Cash/sh0.25 P/C41.36 EPS next 5Y- ROE79.70% 52W Range8.50 - 25.46 Perf YTD-25.76%
Dividend- P/FCF- EPS past 5Y5.10% ROI-121.90% 52W High-58.92% Beta1.63
Dividend %- Quick Ratio1.00 Sales past 5Y190.70% Gross Margin98.90% 52W Low23.06% ATR0.62
Employees258 Current Ratio1.00 Sales Q/Q-49.60% Oper. Margin-85.90% RSI (14)43.80 Volatility5.61% 5.79%
OptionableYes Debt/Eq- EPS Q/Q-107.40% Profit Margin- Rel Volume0.42 Prev Close10.54
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume1.60M Price10.46
Recom2.40 SMA20-3.91% SMA50-7.02% SMA200-22.21% Volume674,340 Change-0.76%
Oct-20-20Initiated BofA Securities Buy $21
Aug-21-20Reiterated H.C. Wainwright Buy $34 → $32
Aug-14-20Reiterated Maxim Group Buy $25 → $20
May-06-19Initiated Cantor Fitzgerald Overweight $26
Jul-12-18Initiated Seaport Global Securities Buy $30
Mar-23-18Downgrade Wedbush Outperform → Neutral $47 → $19
Mar-05-18Downgrade Needham Buy → Hold
Nov-08-17Initiated H.C. Wainwright Buy $30
May-11-17Downgrade Cantor Fitzgerald Buy → Neutral $21 → $15
Mar-17-17Reiterated Needham Buy $24 → $22
Mar-17-17Reiterated Maxim Group Buy $19 → $22
Nov-16-16Reiterated Wedbush Outperform $56 → $47
Nov-10-16Reiterated Needham Buy $28 → $24
Aug-10-16Reiterated Maxim Group Buy $30 → $19
Jun-03-16Initiated Cantor Fitzgerald Buy $21
Mar-02-16Reiterated Needham Buy $30 → $28
Feb-29-16Reiterated Wedbush Outperform $65 → $62
Nov-11-15Reiterated Needham Buy $32 → $30
Aug-18-15Reiterated WBB Securities Strong Buy $60 → $75
Aug-10-15Initiated ROTH Capital Buy $38
Oct-28-20 09:00AM  
Oct-22-20 08:00AM  
Oct-20-20 09:56AM  
Oct-16-20 08:30AM  
Oct-15-20 08:00AM  
Oct-01-20 09:00AM  
Sep-14-20 02:10PM  
Sep-11-20 07:00AM  
Sep-09-20 08:45AM  
Sep-03-20 09:38AM  
Aug-31-20 08:18AM  
08:00AM  
Aug-12-20 12:35PM  
06:30AM  
Aug-11-20 08:20AM  
Aug-10-20 05:45PM  
04:12PM  
04:01PM  
12:25PM  
11:41AM  
11:35AM  
09:01AM  
07:30AM  
Aug-06-20 12:30PM  
Jul-26-20 06:27AM  
Jul-15-20 03:06PM  
Jun-24-20 04:27PM  
Jun-12-20 08:30AM  
Jun-11-20 08:45AM  
Jun-08-20 02:28PM  
May-26-20 06:45PM  
May-14-20 09:00AM  
May-12-20 06:01AM  
May-11-20 06:55PM  
04:02PM  
May-08-20 08:36AM  
May-05-20 07:00AM  
Mar-11-20 03:38PM  
Mar-04-20 10:00AM  
Mar-02-20 05:35PM  
04:03PM  
04:01PM  
Feb-24-20 07:00AM  
Feb-11-20 09:35AM  
08:30AM  
Feb-03-20 03:49PM  
Jan-23-20 05:30PM  
Dec-20-19 05:16PM  
Dec-18-19 08:30AM  
Dec-16-19 08:30AM  
Dec-13-19 09:30AM  
Dec-10-19 08:30AM  
Dec-05-19 07:14AM  
Dec-04-19 04:11PM  
10:42AM  
10:38AM  
07:00AM  
Dec-03-19 11:45PM  
Nov-20-19 08:45AM  
Nov-19-19 08:45AM  
Nov-16-19 08:10AM  
Nov-13-19 02:00PM  
09:59AM  
Nov-12-19 05:35PM  
04:02PM  
Nov-11-19 05:16PM  
Nov-08-19 08:30AM  
Nov-07-19 05:45PM  
08:30AM  
Nov-06-19 08:15AM  
Nov-04-19 03:00PM  
02:30PM  
07:50AM  
Nov-01-19 11:22AM  
Oct-29-19 09:00AM  
Oct-28-19 08:45AM  
Oct-21-19 09:46AM  
Oct-18-19 04:31AM  
Oct-01-19 08:30AM  
Sep-25-19 09:01PM  
08:45AM  
Sep-16-19 08:45AM  
Sep-11-19 08:45AM  
Sep-10-19 10:01AM  
08:30AM  
Sep-06-19 07:00AM  
Aug-22-19 10:58AM  
Aug-09-19 08:30AM  
04:23AM  
Aug-08-19 06:20PM  
04:02PM  
Aug-05-19 04:02PM  
Aug-01-19 10:32AM  
Jul-31-19 08:30AM  
Jul-26-19 10:33AM  
Jul-24-19 08:45AM  
Jul-11-19 02:46PM  
10:23AM  
08:00AM  
Jun-14-19 11:38AM  
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Cable Thomas J.DirectorMay 13Option Exercise5.925,00029,60040,067May 15 08:00 PM
Cable Thomas J.DirectorMay 13Sale14.405,00071,99935,067May 15 08:00 PM
Hood Leroy E. MD PhDDirectorMar 13Option Exercise5.925,00029,60069,390Mar 17 05:25 PM
Demopulos Peter A MDDirectorDec 14Option Exercise7.563,33425,205188,516Dec 17 09:40 PM
Hood Leroy E. MD PhDDirectorDec 14Option Exercise7.5610,00075,60064,390Dec 17 09:40 PM
Cable Thomas J.DirectorDec 03Option Exercise7.5610,00075,60045,067Dec 05 09:15 PM
Cable Thomas J.DirectorDec 03Sale14.4110,000144,14835,067Dec 05 09:15 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.